Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients (ALD)
Phase IV Study Safety & Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients.
Sponsor: Clayton Sleep Insititute
Terminated
Withdrawn by Investigator, protocol in revision
Other Mild Alzheimer's Disease trials with similar outcome
A PHASE4 clinical study on Mild Alzheimer's Disease, this trial is terminated or withdrawn. The trial is conducted by Clayton Sleep Insititute and has accumulated 7 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Clayton Sleep Insititute
- St. Louis University
For direct contact, visit the study record on ClinicalTrials.gov .